In 2019, commercial pharmaceutical companies operate in a progressively changing environment; the ever-increasing pressure to reduce healthcare costs puts the industry under even greater scrutiny from both the public and regulatory bodies.
In an Internet of Things (IoT) world, objects – from doorknobs to pill capsules – have computerized eyes and brains which can talk to each other and to us.
In this digital age, the term “data” can often be much like a loaded question; many industries have an overabundance of raw data available but a distinct lack of understanding of how to deal with that data. The pharma and biotech industries are no exception.
In the era of modern technology, most Clinical Trial methodologies still rely on paper-based data collections. However, the recent trends show that the Clinical Trial market is growing like never before and by 2024; the market will reach $2 billion. Dated technology and processes will no longer be able to handle such explosive growth. Fortunately, […]
In response to the rapidly growing influence of managed care, the pharma industry has undergone significant transformation.
Struggling with how to best use data in your pharma or biotech company? Or, are you wondering if your current data management systems (or lack thereof) are helping or hindering?
Every consumer expects businesses to understand them, listen to their requirements, and provide required services. The healthcare industry is no exception – this sector often requires more time to serve the prescriber and patient’s needs effectively.
Artificial Intelligence, or AI for short, has been one of those buzzwords that’s been circulating throughout the healthcare industry. Most recently, it has been widely considered to be extremely beneficial for drug discovery and in clinical trials.
Clinical trials are still the only viable way to bring new medicines and products to market. However, successful clinical trials require participants (subjects), locating, and screening-eligible participants. This can be challenging.
According to an EvaluatePharma study, two-thirds of all drug launches failed to meet pre-launch expectations in sales their first year on the market.